Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
Stock Information for PLUS THERAPEUTICS Inc.
Please wait while we load your information from QuoteMedia.
More Recent News About PLUS THERAPEUTICS Inc.
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹??Re) Obisbemeda for the Treatment of Leptomeningeal Metastases
Plus Therapeutics Provides Updates on ReSPECT(TM) Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Plus Therapeutics to Provide Update on ReSPECT(TM) Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Plus Therapeutics Announces Selection of "Rhenium (186Re) Obisbemeda" as International Non-Proprietary Name for 186RNL